Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maze Therapeutics (MAZE) Operating Leases (2024 - 2026)

Maze Therapeutics' Operating Leases history spans 3 years, with the latest figure at $17.6 million for Q1 2026.

  • On a quarterly basis, Operating Leases fell 17.01% to $17.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $17.6 million, a 17.01% decrease, with the full-year FY2025 number at $18.5 million, down 15.84% from a year prior.
  • Operating Leases hit $17.6 million in Q1 2026 for Maze Therapeutics, down from $18.5 million in the prior quarter.
  • Over the last five years, Operating Leases for MAZE hit a ceiling of $22.0 million in Q4 2024 and a floor of $17.6 million in Q1 2026.
  • Historically, Operating Leases has averaged $19.8 million across 3 years, with a median of $19.9 million in 2025.
  • Biggest five-year swings in Operating Leases: dropped 15.84% in 2025 and later fell 17.01% in 2026.
  • Tracing MAZE's Operating Leases over 3 years: stood at $22.0 million in 2024, then dropped by 15.84% to $18.5 million in 2025, then fell by 5.18% to $17.6 million in 2026.
  • Business Quant data shows Operating Leases for MAZE at $17.6 million in Q1 2026, $18.5 million in Q4 2025, and $19.4 million in Q3 2025.